Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
about
Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.MiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor.6-Paradol and 6-Shogaol, the Pungent Compounds of Ginger, Promote Glucose Utilization in Adipocytes and Myotubes, and 6-Paradol Reduces Blood Glucose in High-Fat Diet-Fed Mice.Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonistsNovel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.Pharmacotherapy of 'treatment resistant' type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Novel Anti-fibrotic Therapies.Anti-diabetic activity of stigmasterol from soybean oil by targeting the GLUT4 glucose transporter.Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance.Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.Differences in the neovascular potential of thymus versus subcutaneous adipose-derived stem cells from patients with myocardial ischaemia.Incretin-Based Therapies: Revisiting Their Mode of Action.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin.Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.Role of L-arginine/NO/cGMP/KATP channel signaling pathway in the central and peripheral antinociceptive effect of thymoquinone in rats.An MG53-IRS1-interaction disruptor ameliorates insulin resistance.Different sulfonylureas induce the apoptosis of proximal tubular epithelial cell differently via closing K channel
P2860
Q30234897-52C8C64D-62A3-4088-978E-A0946667D142Q33903029-F6407309-DA0C-4E01-8849-2D102862C3BEQ37631637-B52DCDD0-611F-4344-AED4-C3A86A3E1229Q38885174-B3489A83-3CEF-4FFB-B61C-ADB8F8FC4738Q39000136-139698A6-C469-4FDD-97B1-5B2EDB9D7584Q39170345-B4B8494D-108E-48C6-B37B-506636ABE4EAQ39255188-062DAD97-0688-4FB1-A934-86F8AB0FB3C3Q39377055-451238D3-A8AB-4740-A4FE-C44D5209B348Q42364198-827BE858-F354-4975-BF75-65AB36C5CE89Q42380223-5E56D632-945E-40E3-BA26-094202DE56A9Q47154668-317F1E91-087E-4CC3-B573-992F1FEB6961Q47652080-245D72B5-7C48-4A07-A190-B6C28E5B053DQ47662118-B24C8829-4E94-4393-8B65-6C84C223BDE2Q47868323-FC0D2488-626D-43AF-9897-75DE5D1B726CQ48043450-AD7BA44F-FADC-46AC-8382-012903F88A6BQ48292533-D6A14EAC-2159-404E-A59A-3E569D106307Q50958192-7DEF206C-4F2B-4C62-A544-B9B8AF6A648BQ51731100-6DECB004-4599-43A8-943A-4D46868DD245Q55305243-F6164F0D-4FDB-4766-B207-B9B73F9A6A03Q55400599-F37DBCA9-A01F-4D37-A72E-8970D8426B08Q58765732-8C0D4629-5B24-41D3-9B64-7C096555BCFA
P2860
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@ast
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@en
type
label
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@ast
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@en
prefLabel
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@ast
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@en
P2860
P356
P1476
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
@en
P2093
Anthony H Barnett
P2860
P2888
P304
P356
10.1038/NRENDO.2016.86
P577
2016-06-24T00:00:00Z